Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro

BACKGROUND: Rasagiline, a new drug developed to treat Parkinson's disease, is known to inhibit monoamine oxidase B. However, its metabolite R-(-)-aminoindan does not show this kind of activity. The present series of in vitro experiments using the rat hippocampal slice preparation deals with eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimpfel, W, Hoffmann, JA
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051903/
https://www.ncbi.nlm.nih.gov/pubmed/21338509
http://dx.doi.org/10.1186/1471-2210-11-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051903/
https://www.ncbi.nlm.nih.gov/pubmed/21338509
http://dx.doi.org/10.1186/1471-2210-11-2

Ejemplares similares